News & Events

Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully…

Read more
PEGSBoston 2022

Speaker: Dr. Qingcong Lin, CEO, Biocytogen Boston Corporation, Biocytogen Boston Corp Time: 9:30 am EDT, May 2nd Talk title: Generation of Fully Human Antibodies for…

Read more
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers

BEIJING and SHANGHAI, April 18, 2022/PRNewswire/--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced a collaboration agreement with CtM Biotech (Shanghai) Co., Ltd…

Read more
Webinar: Generation and discovery of high affinity antibodies

Our webinar “Generation and discovery of high affinity antibodies” was live on April 27, 2022 at 1PM EDT. In this webinar, we will Introduce Biocytogen’s…

Read more
Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy

BEIJING, April 6, 2022 - Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No. YH003005) of YH003 (anti-CD40…

Read more
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

Beijing, China and Heidelberg, Germany, March 28, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as “Biocytogen”) announced the opening of the Biocytogen…

Read more
AACR 2022

  Attend the meeting Our Poster Session Talk to us at booth 1043! The AACR Annual Meeting is the focal point of the cancer research…

Read more
Experimental Biology 2022

                          Talk to us at booth 830! Experimental Biology (EB) is the annual…

Read more
Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia

BEIJING, CHINA, March 8, 2022 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial…

Read more
Webinar: Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice

Our webinar “Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice” was live on March 16, 2022 at 11AM EDT.…

Read more
Back to top